Indivior files patent lawsuits against generic rivals

Indivior plc said its US subsidiary Indivior Inc filed patent lawsuits against Dr. Reddy’s, Actavis, Par, Alvogen, Teva, and Mylan for alleged infringement of a US patent relating to their respective proposed generic versions of Indivior’s Suboxone (buprenorphine and naloxone) Sublingual Film product.

Opioid addiction treatment Suboxone generates about 80% of Indivior’s revenue, according to Reuters data.

Indivior CEO Shaun Thaxter said: “We strongly believe that these companies with their proposed generic products infringe on our intellectual property and we are taking the appropriate actions to enforce our position.

“Toward that end, we are also preparing our appeal against the recent decision in the lawsuit against Dr. Reddy’s (pending in the U.S. District Court for the District of Delaware), and expect to file our appeal with the U.S. Court of Appeals for the Federal Circuit shortly after the District Court judgement is entered.”